The biology of ageing in relation to acute myeloid leukemia (AML) in older patients

The biology of ageing in relation to acute myeloid leukemia (AML) in older patients - Ageing of the hematopoietic system

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39102

Enrollment

Registered

2010-11-24

Start date

2010-11-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AML

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - a doctor's diagnosis of normal general health - not suffer from a hematological disease - people older than 60 years of age who get a total hip replacement - healthy volunteer

Exclusion criteria

Exclusion criteria: - patients suffering from a hematological disease

Design outcomes

Primary

Measure	Time frame
We aim to identify molecular pathways which are activated upon ageing to protect stem cells against damage but are down-regulated in AML cells of older patients.	—

Secondary

Measure	Time frame
We aim to explore whether oncogenic hits have different molecular and cellular consequences depending on the age of the target cell.	—

Countries

Netherlands

Outcome results